Azacitidine in AML: A treatment option?

  • Huls G
  • 19


    Mendeley users who have this article in their library.
  • 7


    Citations of this article.


In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Gerwin Huls

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free